FDA Approves MenQuadfi Meningococcal Vaccine for Six-Week-Old Infants
The U.S. Food and Drug Administration (FDA) has licensed Sanofi’ SA’s four-valent MenQuadfi meningococcal vaccine for use in infants aged six weeks to 23 months old to prevent invasive meningococcal disease. Previously approved for children aged two and older, MenQuadfi is now the first meningococcal vaccine included on the U.S. Centers for Disease Control and […]
FDA Approves GSK’s 5-in-1 Meningococcal Vaccine
On Feb. 14, 2025, British pharmaceutical and biotechnology company GSK plc announced that the U.S. Food and Drug Administration (FDA) approved its 5-in-1 meningococcal vaccine PENMENVY for licensure and use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of the bacterium Neisseria meningitidis (A, B, C, W, and Y), which […]
CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine
On Oct. 20, 2023, Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new pentavalent meningococcal vaccine, Penbraya, which targets five meningococcal serogroups (A, B, C, W and Y) that most commonly cause meningococcal disease in adolescents and young adults 10-25 years old. Penbraya, is recommended to be given in two […]